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This is a critical time in neurotherapeutics. The prevalence of neurological disease, such as dementia, stroke, and
peripheral neuropathy, is large and growing consequent to the aging population. The personal and societal impact
of these disorders is enormous, and the number of novel therapies in the pipeline for these disorders has been con-
tracting. Support for the development of neurotherapies must continue from the bench to their ultimate place at the
bedside. Academic medicine must continue to play a critical role, in league with industry and government, in the
development of novel neurotherapies desperately needed by an ever-expanding population. Critical steps include
the identification and adoption of reliable, valid, and reproducible biomarkers to serve as primary endpoints in clini-
cal trials of neurological disease.
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The burden of neurological disease is remarkable inboth its impact on the quality of life and its cost.
This has been particularly true in developed countries
where an increasing life expectancy has resulted in sub-
stantial increases in the prevalence of diseases that chiefly
afflict the elderly, such as stroke and dementing disease.
Were a critical prospective analysis to be done on the
elderly population, it is likely that few would escape
some form of neurological ailment, with many individu-
als suffering from more than one.
The nature of neurological disorders varies with
age. Autistic spectrum disorders (ASDs), cerebral palsy,
and Tourette syndrome are among many disorders that
present in childhood. A conservative estimate of the fre-
quency of ASDs is 27.5 per 10,000, with newer surveys
suggesting that it is as high as 60 per 10,000 individu-
als.1 A surveillance study of ASDs during 2008 from 14
sites in the United States found a prevalence of 11.3 per
1,000 (1 in 88) children aged 8 years old.2 With respect
to cerebral palsy, studies from Europe and the United
States reveal a median prevalence of 2.4 per 1,000.3 An
increase in preterm births, which has been occurring in
the United States in the recent past,4 is associated with
an even higher prevalence of cerebral palsy. The reported
prevalence of Tourette syndrome is age-dependent and
has varied widely from study to study, but a median esti-
mated prevalence of 3.5 per 1,000 has been proposed.3
One in 5 children experience transient tics, and 1 in 100
develop Tourette syndrome.5
Among the more common neurological disorders
across the age spectrum are migraine headache and epi-
lepsy. The 1-year prevalence per 1,000 for migraine
derived from an analysis of multiple epidemiological
studies was 121.3 The 1-year prevalence in a study con-
ducted in Philadelphia revealed that 17.2% of women
and 6.0% of men were migraineurs, with the highest
prevalence between the ages of 30 and 49 years.6 The
economic impact of migraine is substantial, with indirect
costs outweighing the cost of treatment.7 Approximately
1% of the US population will have epilepsy by age 20
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years, with >2=3 having onset in childhood.
8,9 The inci-
dence of seizures is high in the first year of life, but high-
est in individuals age 75 years or greater,9 which
represents an increasing percentage of the population of
the developed world. The 1-year prevalence per 1,000
for epilepsy in the United States is estimated at 7.1,3 and
the cumulative incidence of all unprovoked seizures
through age 74 years is 4.1%.10
Traumatic brain injury (TBI), spinal cord injury
(SCI), and multiple sclerosis (MS) lead to the highest
rate of neurologic disability among young adults. TBI
has a median annual incidence in the United States of
101 per 100,0003 and is notably frequent among veter-
ans returning from the Iraq and Afghanistan wars. In a
Veterans Administration study of 327,388 veterans of
these 2 recent wars, 6.7% had been diagnosed with TBI,
and 89% of those patients carried a psychiatric diagno-
sis.11 Similarly, chronic traumatic encephalopathy has
been recognized with increased frequency in individuals
engaged in contact sports.12,13 SCI from trauma resulting
in complete or incomplete functional interruption of spi-
nal pathways has a median annual incidence of 4.5 per
100,000 and a prevalence of 72 per 100,000 in the
United States.3 The median estimate of the annual inci-
dence of MS in the United States is 4.2 per 100,000
(range5 0.8–12.0), with prevalence estimated between
47.2 and 109.5 per 100,000.14 Both the incidence and
prevalence are twice as high in women as in men, and
the peak age of onset is approximately 30 years.3
In the 20th century, the age-adjusted death rate of
Americans declined by about 74% and the life expect-
ancy increased 56%.15 The aging population has been
accompanied by an increase in neurological disorders,
particularly stroke and neurodegenerative conditions,
such as Alzheimer and Parkinson disease. In 2009, the
life expectancy at birth in the United States was 78.5,
and for a person age 65 years old, 19.2 years.16 In 2010,
the Department of Health and Human Services esti-
mated that there were >40 million individuals in the
United States >65 years old, constituting 13.0% of the
total population.17 By 2030, that number will nearly
double to >71 million and represent 19.7% of the pop-
ulation.17 Data collected from 17 series with >15,000
persons aged 60 years or more revealed a mean incidence
of moderate to severe dementia of 4.8%.18 The incidence
rate for dementia in Rochester, Minnesota was 187 per
100,000 and for Alzheimer disease was 123 per
100,000.19 The frequency of Alzheimer disease increases
with advanced age; for those 60 to 69 years old, the
prevalence approximates 300 per 100,000, for those 70
to 79 years old, the prevalence is 3,200, and for those
>80 years old, the prevalence is 10,800.20 In 2010, 4.7
million people aged 65 years or older in the United
States had Alzheimer disease,21 accounting for 42% of
the chronic conditions among persons living in residen-
tial facilities.22 By 2050, it is estimated that there will be
13.8 million people with Alzheimer disease in the United
States.21
Estimates from several studies of the incidence and
prevalence of Parkinson disease indicate that the median
incidence is 160 (range5 62–332) per 100,000 for per-
sons aged 65 or older, with a prevalence rate of 9.5 per
1,000 (range5 7.0–43.8).3 It is estimated that Parkinson
disease affects about 1 million people in the United
States.20
Regarding cerebrovascular disease, the median
annual incidence of first-ever stroke is 183 per 100,000,
with the rate roughly doubling every decade during
adulthood. The prevalence of stroke, as determined in a
study from Rochester, Minnesota, was 1% of the popula-
tion,23 and nationwide studies suggest that it approaches
2% for persons aged 25 to 74 years.24 Annually, 700,000
people in the United States suffer a stroke, about 1 per-
son every 45 seconds, and >1=2 die within 8 years of
their stroke.25 In 2010, there were 4.7 million people liv-
ing with stroke in the United States.25 Stroke accounted
for 11% of the persons living in residential facilities.22
The neurological disorders described above are but
a short list of some of the more common neurological
afflictions. Disorders of the peripheral nervous system,
such as Guillain–Barre disease, chronic inflammatory
demyelinating peripheral neuropathy, diabetic neuropa-
thy, postherpetic neuralgia and other pain syndromes,
and myasthenia gravis, as well as other central nervous
system (CNS) disorders, such as amyotrophic lateral scle-
rosis, are not encompassed in this review. It also does not
address the 20% of orphan diseases that are neurological;
neurological disease has the third-highest number of
orphan product designations.26 When all these condi-
tions are considered in aggregate, it reveals a substantial
burden of neurological disease, with a significant impact
on health and well-being coupled with enormous direct
and indirect financial costs. Neurological disorders
accounted for a substantial amount of the $2.1 trillion
dollars of direct cost of personal health care expenditures
in the United States in 2009.16
Difficulties of Bringing Drugs to Market
About 85% of all drug therapies fail in clinical trial, and
on average only 25 to 30 new molecular entities are
approved in the United States annually.27,28 Data col-
lected by the US Food and Drug Administration indicate
that over the past 20 years there was a spike in new
drug approvals in the mid-1990s (53 in 1996), with a
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flattening out in the past decade.29 In the past 3 years,
the number of annual new drug approvals has averaged
approximately 1=3 of the approval rate of the preceding 2
decades.29 Nonetheless, the cost of research and develop-
ment has continued to increase during this time, with an
inverse relation to the number of approved new drugs.
The expense of research and development in 1996 was
$16.9 billion, compared to $49.5 billion in 2011, roughly
a 3-fold increase (Fig 1).30 The capitalized clinical develop-
ment costs for CNS drugs is higher than drugs in any other
category31; estimates for the cost of research and develop-
ment for bringing a new medical entity to market averages
as much as $1.8 billion.32 In 2005 in the United States,
industry contributed $7.8 billion US dollars for the devel-
opment of neurotherapeutic agents, exceeding the contri-
butions for any other therapeutic area.33,34
The process of drug development is complex and
costly. The initial phase is exploratory research for drug
discovery. In this phase, efforts are made to identify bio-
logical pathways important to disease pathogenesis that
can be modified by a specific drug. Once such a pathway
and targeting agent is identified, it must be demonstrated
that the drug reaches the appropriate target tissue, that it
affects the pathway of interest, and that there is a thera-
peutic window for the drug. Clinical research must also
determine the pharmacokinetics and pharmacodynamics
for the drug to identify its optimal dosing. Following test-
ing in animals, a sequential series of clinical trials with
increasing numbers of human volunteers is undertaken.
New neurological therapies have a higher attrition
than therapies in any other area, other than oncology.35
Only 8% of CNS drugs ever make it to clinical trials,
roughly 1=2 the rate of drugs in other fields.
31 Further-
more, CNS drugs tend to fail late in development,31 sub-
stantially increasing their cost and the financial risk to
companies working in the CNS drug space. The proba-
bility of success for a new neurotherapeutic agent has
been calculated at 2.85%.35
The approval success rate for therapies varies widely
by discipline. For instance, systemic anti-infectious disease
therapies have nearly 33 the likelihood of making it to
the market as therapies for neurological disorders.36 Addi-
tionally, the time to market for CNS drugs from clinical
trials (Fig 2) through the approval process averages 10.0
years (8.1 in clinical trials and 1.9 years in the approval
phase), substantially exceeding that for any other therapeu-
tic area.36 Therefore, there are economic disincentives for
industry to pursue neurological therapies, and as such,
neurological therapies are considered a high-risk invest-
ment with long, costly development phases and low prob-
abilities of approval. Because of these considerations, in
the past 3 years, many large pharmaceutical companies,
including AstraZeneca, GlaxoSmithKline, Pfizer, Merck,
Sanofi, and Novartis, have significantly downsized their
neuroscience commitment.37,38
FIGURE 1: Annual research and development (R&D) spending versus new drug approvals over the past 20 years. The number
of new drug approvals, reported in number of new molecular entities (NMEs; gray bars), is plotted against the amount of
money spent on pharmaceutical R&D, reported in billions of United States dollars (USD; blue line). [Color figure can be viewed
in the online issue, which is available at www.annalsofneurology.org.]
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Decreasing the time and financial investment in
bringing neurological therapies to the marketplace will
likely require the development and support of bio-
markers. For instance, biomarkers could potentially assist
in identifying particular populations that are at high risk
of disease activity or rapid disease advancement. Bio-
markers may also enrich study populations by increasing
their homogeneity. Biomarkers could potentially provide
not only more objective measures of disease activity than
clinical batteries, but also more sensitive measures for
early presymptomatic disease (eg, magnetic resonance
imaging in MS).39 Biomarkers may also play a role in
drug safety (for example, JC virus antibody testing to
identify risk of progressive multifocal leukoencephalop-
athy with natalizumab treatment for MS) and may pre-
dict the rapidity of disease progression. The outcome
measures for clinical trials need to be validated, sensitive
to change, reliable having low inter- and intrarater vari-
ability, and practical. Identification of meaningful bio-
markers will be important for achieving those goals.
Solutions for Increasing the Drugs Available
for Neurological Disorders
Increasing drug discovery for neurological disorders
requires a multifaceted approach. Academic neurological
societies must play a leading role in this neurotherapeutic
endeavor and support the domain of neurologists who
have contributed to the discovery of these agents, their
clinical testing, and their use at the bedside. Scientists
must first identify the hurdles in shepherding a novel
neurotherapy from the bench to the patient’s bedside,
and then implement measures to overcome these
challenges.
Direct measures to promote neurotherapeutics by
the academic neurological community (Table 1) include
targeting meeting programs for drug discovery, develop-
ing and training fellows for translational neuroscience,
and promoting publications that advance the field. Addi-
tionally, academic neurological societies can advocate pri-
oritizing translational neuroscience within academia.
Academic leaders may also serve at the forefront of devel-
oping public–private partnerships to develop disease
models, outcome assessment tools, biomarkers, and
therapies. To facilitate the development of neurological
therapies, these individuals must engage with many enti-
ties, including funding agencies, such as the National
Institutes of Health and private foundations, with regula-
tory agencies, such as the US Food and Drug Adminis-
tration, and with industry. In addition, the neurological
academic leadership needs to play a pivotal role in
informing governmental policy makers that support of
investigations in neurotherapeutics has high value regard-
ing quality of life, survival, and societal costs.
As appropriately addressed by Leppert and Glanz-
man,40 among the greatest challenges for neurological
therapies is determining reliable and measurable
FIGURE 2: Mean clinical and approval phase times for
approved new molecular entities and significant biologicals,
2005–2009, grouped by therapeutic class. Note that the
anti-infective group does not include acquired immunodefi-
ciency syndrome (AIDS) antivirals. CNS5 central nervous
system. Reprinted by permission from Macmillan: Clin Phar-
macol Ther 2011;89:183–188, copyright 2011.36
TABLE 1. Recommendations to Improve
Neurotherapeutic Development
Engagement of neurological societies
Promote educational programs for therapeutic
discovery during national meetings
Develop training programs in translational
neuroscience for early career neurologists
Advocate for translational research
Academic leaders
Support development of public–private
partnerships
Fundraising
Enhance communication among National
Institutes of Health, US Food and Drug
Administration, and industry
Political advocacy to educate policy makers
Research focus
Enhance clinical trial endpoints
More rigorous clinical endpoints
Biomarker discovery
Other approaches
Promotion of federal and industry partnerships
specific for therapy development
Tax incentives for neurotherapeutics
Increased patent length for neurotherapeutics
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endpoints for clinical trials. The endpoints for neurologi-
cal and psychiatric disease often lack the precision and
validity observed with those employed for other forms of
therapy. These endpoints are often dependent on soft
psychophysical measures, rater dependency, and clinical
phenomenology, and may be affected by culture and lan-
guage.40 Substituting biomarkers as primary endpoints,
such as the use of magnetic resonance imaging for MS,
may decrease the expense and improve the facility and
speed with which studies can be performed. Academic
neurology should consider strongly encouraging regula-
tory agencies to permit neurotherapeutic trials to utilize
such biomarkers when they have been proven scientifi-
cally valid, reliable, reproducible, and predictive of dis-
ease activity.
Other approaches that might be considered for fos-
tering neurological therapies include encouraging partner-
ships between federal funding agencies and industry for
the performance of clinical trials, providing tax incentives
to pharmaceutical companies engaged in neurotherapeu-
tic development, and increasing the patent length on
therapies to assist in the financial viability for the initial
investment.
Conclusions
This is a critical time in neurotherapeutics. The impera-
tive for agents that treat neurological disorders is large
and expanding. Continued research is needed to identify
the most sensitive and specific clinical outcome measures
and biomarkers of safety and efficacy. A concerted com-
mitment by academic medicine, industry, and govern-
ment will fulfill the promise of new, effective, and safe
therapies for many neurological diseases.
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